Johnson & Johnson-backed Janssen Pharmaceutica, a pharmaceutical company, agreed to acquire product candidates from Yumanity Therapeutics, a clinical-stage biopharmaceutical company, for $26m. “After evaluating Yumanity’s strategic alternatives, management and our Board of Directors believes that the proposed transactions are in the best interest of Yumanity’s stockholders. We are excited that our lead clinical-stage neurology asset and unpartnered assets will continue to be developed and we are very enthusiastic about Kineta’s innovative oncology pipeline," Richard Peters, Yumanity President and CEO.